Hovione has acquired a formulation facility located next to its existing Loures, Portugal facility for process chemistry and particle engineering, the company said. The new facility will be able to produce clinical trial supplies and commercial batches for both oral and inhalation drug products, including highly potent APIs.
Hovione VP of R&D Filipe Gaspar commented, “Over the last decade we have built great knowledge in developing final dosage forms in the area of dry powder inhalation and oral dosage forms and have installed state-of-the-art formulation equipment to support these activities. Adding to our drug substance and particle engineering capabilities this new plant expands our integrated offer and technological capabilities to provide the best service to our customers.”
CEO Guy Villax added, “With this investment we will be able to expand our offerings and provide our clients with new services. I am sure our customers will value the option of not having to ship the material that comes out of our reactors and spray dryers to outside the walls of our site and away from our trusted quality culture. This is also a great way to speed up the entire CMC development to meet the needs of the growing number of accelerated programs that our clients ask us to deliver on.”
Read the Hovione press release.
